Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* You have non-small cell lung cancer that has come back (relapsed) after initial treatment with surgery and chemotherapy.~* You have good kidney, liver, and bone marrow organ function.~* You are fully active or able to carry out light work such as housework or office work.~Exclusion Criteria:~* You have received pemetrexed or gemcitabine in the past for lung cancer~* You are currently receiving another treatment for your relapsed lung cancer, or have had chemotherapy or certain other therapies for relapsed lung cancer in the past~* You are unable to take corticosteroid drugs like dexamethasone~* You are unable or unwilling to take the folic acid pills or Vitamin B12 injections that are required for the study~* You are unable to stop taking aspirin or other drugs that control inflammation for certain periods of time during the study~* You have had a heart attack in the last 6 months, or have other heart problems that are not controlled with medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Less Than One Year: Pemetrexed (Type: EXPERIMENTAL): Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
- Less Than One Year: Pemetrexed + Gemcitabine (Type: EXPERIMENTAL): Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
- One Year or Greater: Pemetrexed + Carboplatin (Type: EXPERIMENTAL): Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
- One Year or Greater: Pemetrexed + Gemcitabine (Type: EXPERIMENTAL): Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).